116 results on '"Shinjo, Samuel K."'
Search Results
2. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
- Author
-
Silva, Clovis A., Medeiros-Ribeiro, Ana C., Kupa, Leonard V. K., Yuki, Emily F. N., Pasoto, Sandra G., Saad, Carla G. S., Fusco, Solange R. G., Pereira, Rosa M. R., Shinjo, Samuel K., Halpern, Ari S. R., Borba, Eduardo F., Souza, Fernando H. C., Guedes, Lissiane K. N., Miossi, Renata, Bonfiglioli, Karina R., Domiciano, Diogo S., Shimabuco, Andrea Y., Andrade, Danieli C. O., Seguro, Luciana P. C., Fuller, Ricardo, Sampaio-Barros, Percival D., Assad, Ana P. L., Moraes, Julio C. B., Goldenstein-Schainberg, Claudia, Giardini, Henrique A. M., Silva, Henrique C., Martins, Victor A. O., Villamarin, Lorena E. B., Novellino, Renata S., Sales, Lucas P., Araújo, Carlo S. R., Silva, Matheus S. R., Filho, Dilson M. N., Lopes, Marta H., Duarte, Alberto J. S., Kallas, Esper G., Aikawa, Nadia E., and Bonfa, Eloisa
- Published
- 2022
- Full Text
- View/download PDF
3. Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis
- Author
-
Casa, Francesca Della, Vitale, Antonio, Guerriero, Silvana, Sota, Jurgen, Cimaz, Rolando, Ragab, Gaafar, Ruscitti, Piero, Pereira, Rosa Maria R., Minoia, Francesca, Del Giudice, Emanuela, Emmi, Giacomo, Lomater, Claudia, Monti, Sara, Canofari, Claudia, Gaggiano, Carla, Alessio, Giovanni, Miserocchi, Elisabetta, Conforti, Alessandro, Dagostin, Marilia A., Mapelli, Chiara, Paroli, Maria Pia, Parretti, Veronica, Albano, Valeria, Favale, Rosa, Marelli, Luca, Hegazy, Mohamed Tharwat, Cipriani, Paola, Antonelli, Isabele P. B., Caggiano, Valeria, Aragona, Emma, Laymouna, Ahmed Hatem, Tosi, Gian Marco, Tarsia, Maria, Cattalini, Marco, La Torre, Francesco, Lopalco, Giuseppe, Więsik-Szewczyk, Ewa, Frassi, Micol, Gentileschi, Stefano, Giordano, Heitor F., Frediani, Bruno, Shinjo, Samuel K., Rigante, Donato, Sfikakis, Petros P., Balistreri, Alberto, Hussein, Mohamed A., Amin, Rana Hussein, Cantarini, Luca, and Fabiani, Claudia
- Published
- 2022
- Full Text
- View/download PDF
4. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
- Author
-
Aikawa, Nadia E, Kupa, Leonard V K, Pasoto, Sandra G, Medeiros-Ribeiro, Ana C, Yuki, Emily F N, Saad, Carla G S, Pedrosa, Tatiana, Fuller, Ricardo, Shinjo, Samuel K, Sampaio-Barros, Percival D, Andrade, Danieli C O, Pereira, Rosa M R, Seguro, Luciana P C, Valim, Juliana M L, Waridel, Filipe, Sartori, Ana Marli C, Duarte, Alberto J S, Antonangelo, Leila, Sabino, Ester C, Menezes, Paulo Rossi, Kallas, Esper G, Silva, Clovis A, and Bonfa, Eloisa
- Published
- 2022
- Full Text
- View/download PDF
5. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
- Author
-
Medeiros-Ribeiro, Ana C., Aikawa, Nadia E., Saad, Carla G. S., Yuki, Emily F. N., Pedrosa, Tatiana, Fusco, Solange R. G., Rojo, Priscila T., Pereira, Rosa M. R., Shinjo, Samuel K., Andrade, Danieli C. O., Sampaio-Barros, Percival D., Ribeiro, Carolina T., Deveza, Giordano B. H., Martins, Victor A. O., Silva, Clovis A., Lopes, Marta H., Duarte, Alberto J. S., Antonangelo, Leila, Sabino, Ester C., Kallas, Esper G., Pasoto, Sandra G., and Bonfa, Eloisa
- Published
- 2021
- Full Text
- View/download PDF
6. Visceral adipose tissue in granulomatosis with polyangiitis: association with disease activity parameters
- Author
-
Furlam, Pedro L., Perez, Mariana O., Franco, Andre S., Caparbo, Valeria F., Shinjo, Samuel K., and Pereira, Rosa M. R.
- Published
- 2021
- Full Text
- View/download PDF
7. Serum Myostatin and Follistatin Levels in Patients With Dermatomyositis and Polymyositis
- Author
-
de Sordi, Cintia M., dos Reis-Neto, Edgard T., Keppeke, Gerson D., Shinjo, Samuel K., and Sato, Emília Inoue
- Published
- 2022
- Full Text
- View/download PDF
8. Mortality predictors in ANCA-associated vasculitis: Experience of a Brazilian monocentric cohort of a rheumatology center
- Author
-
Dagostin, Marilia A., Nunes, Sergio L.O., Shinjo, Samuel K., and Pereira, Rosa M.R.
- Published
- 2021
- Full Text
- View/download PDF
9. Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: Bimodal Pattern of Onset and Treatment Response
- Author
-
Fargetti, Simone, Ugolini-Lopes, Michelle R., Pasoto, Sandra G., Seguro, Luciana P. C., Shinjo, Samuel K., Bonfa, Eloisa, and Borba, Eduardo F.
- Published
- 2019
- Full Text
- View/download PDF
10. Exercise Suppresses The Ubiquitin-proteasome System In The Skeletal Muscle Of Obese Women Following Bariatric Surgery: 2376 Board #295 May 28 3:00 PM - 4:30 PM
- Author
-
Gil, Saulo, Gualano, Bruno, Dantas, Wagner S., Murai, Igor H., Ghosh, Sujoy, Shinjo, Samuel K., Merege-Filho, Carlos, Teodoro, Walcy R., Pereira, Rosa Maria, Benatti, Fabiana B., de Sá-Pinto, Ana L., Lima, Fernanda, de Cleva, Roberto, Santo, Marco A., Kirwan, John P., and Roschel, Hamilton
- Published
- 2020
- Full Text
- View/download PDF
11. Exercise Training Improves Cardiac Autonomic Responses In Obese Women Undergoing Bariatric Surgery: 2130 Board #49 May 28 3:00 PM - 4:30 PM
- Author
-
Roschel, Hamilton, Gil, Saulo, Peçanha, Tiago, Dantas, Wagner, Murai, Igor, Shinjo, Samuel K., Merege-Filho, Carlos, Pereira, Rosa Maria Rodrigues, Benatti, Fabiana B., de Sá Pinto, Ana Lúcia, Lima, Fernanda R., Cleva, Roberto, Santo, Marco A., Rezende, Diego A N, Kirwan, John P., and Gualano, Bruno
- Published
- 2020
- Full Text
- View/download PDF
12. Work situation, work ability and expectation of returning to work in patients with systemic autoimmune myopathies.
- Author
-
Cordeiro, Rafael A, Fischer, Frida M, and Shinjo, Samuel K
- Subjects
EMPLOYEE psychology ,WORK environment ,MUSCLE diseases ,CONFIDENCE intervals ,CROSS-sectional method ,WORK capacity evaluation ,AUTOIMMUNE diseases ,REGRESSION analysis ,DIABETES ,CUTANEOUS manifestations of general diseases ,SEX distribution ,FIBROMYALGIA ,SEVERITY of illness index ,SELF-efficacy ,RESEARCH funding ,QUESTIONNAIRES ,BODY movement ,DESCRIPTIVE statistics ,EMPLOYMENT reentry ,ANXIETY ,JOB performance ,EDUCATIONAL attainment ,ADULTS ,MIDDLE age - Abstract
Objectives To document the work situation, the work ability and the expectation of returning to work among adult patients with systemic autoimmune myopathies (SAMs), and to identify the factors associated with each of these outcomes. Methods Cross-sectional study. The work situation (performing paid work vs out of work) was ascertained via a structured questionnaire. For those who were working, we applied the Work Ability Index (WAI; scale 7–49); and for those who were out of work, we applied the Return-to-Work Self-Efficacy questionnaire (RTW-SE; scale 11–66). Results Of the 75 patients with SAMs included, 33 (44%) were doing paid work and 42 (56%) were out of work. The work situation was independently associated with physical function, assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI). A 1-point increase in the HAQ-DI (scale 0–3) decreased the chance of doing paid work by 66% (95% CI: 0.16, 0.74; P = 0.007). Patients performing paid work had a mean WAI of 33.5 (6.9). The following variables were associated with a decrease in the WAI score in the regression model: female sex (−5.04), diabetes (−5.94), fibromyalgia (−6.40), fatigue (−4.51) and severe anxiety (−4.59). Among those out of work, the mean RTW-SE was 42.8 (12.4). Cutaneous manifestations and >12 years of education were associated with an average increase of 10.57 and 10.9 points, respectively, in the RTW-SE. A 1-point increase in the HAQ-DI decreased the RTW-SE by 4.69 points. Conclusion Our findings highlight the poor work participation in a well-characterized sample of working-age patients with SAMs. Strategies to improve work-related outcomes in these patients are urgently needed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Factors associated with poor outcomes in SLE patients with COVID-19: Data from ReumaCoV-Brazil register.
- Author
-
Carvalho, Joana S, dos Reis Neto, Edgard T, Kakehasi, Adriana M, Ribeiro, Sandra LE, Studart, Samia AS, Martins, Francielle P, Cavalheiro do Espírito Santo, Rafaela, Ranzolin, Aline, Fernandino, Diana C, Dinis, Valquiria G, Sato, Emília I, Resende, Gustavo G, Marinho, Adriana, Mariz, Henrique A, Sacilotto, Nathália C, Ribeiro, Francinne M, Shinjo, Samuel K, Dias, Laiza H, Yazbek, Michel A, and Omura, Felipe
- Subjects
COVID-19 ,MEDICAL personnel ,COVID-19 pandemic ,SYSTEMIC lupus erythematosus ,TREATMENT effectiveness - Abstract
Objectives: To evaluate factors associated with COVID-19 severity outcomes in patients with systemic lupus erythematosus (SLE). Methods: This was a cross-sectional analysis of baseline data of a prospective, multi-stage cohort study—"The ReumaCoV Brazil"—designed to monitor patients with immune-mediated rheumatologic disease (IMRD) during the SARS-CoV-2 pandemic. SLE adult patients with COVID-19 were compared with those without COVID-19. SLE activity was evaluated by the patient global assessment (PGA) and SLE Disease Activity Index 2000 (SLEDAI-2K). Results: 604 SLE patients were included, 317 (52.4%) with COVID-19 and 287 (47.6%) in the control group. SLE COVID-19 patients reported a lower frequency of social isolation and worked more frequently as health professionals. There was no difference in the mean SLEDAI-2K score between groups in the post–COVID-19 period (5.8 [8.6] vs. 4.5 [8.0]; p = 0.190). However, infected patients reported increased SLE activity according to the Patient Global Assessment (PGA) during this period (2.9 [2.9] vs. 2.3 [2.6]; p = 0.031. Arterial hypertension (OR 2.48 [CI 95% 1.04–5.91], p = 0.041), cyclophosphamide (OR 14.32 [CI 95% 2.12–96.77], p = 0.006), dyspnea (OR: 7.10 [CI 95% 3.10–16.23], p < 0.001) and discontinuation of SLE treatment medication during infection (5.38 [CI 95% 1.97–15.48], p = 0.002), were independently associated with a higher chance of hospitalization related to COVID-19. Patients who received telemedicine support presented a 67% lower chance of hospitalization (OR 0.33 [CI 95% 0.12–0.88], p = 0.02). Conclusion: Hypertension and cyclophosphamide were associated with a severe outcome, and telemedicine can be a useful tool for SLE patients with COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
- Author
-
Aikawa, Nadia E, Kupa, Leonard V K, Silva, Clovis A, Saad, Carla G S, Pasoto, Sandra G, Yuki, Emily F N, Fusco, Solange R G, Shinjo, Samuel K, Andrade, Danieli C O, Sampaio-Barros, Percival D, Pereira, Rosa M R, Chasin, Anna C S, Shimabuco, Andrea Y, Luppino-Assad, Ana P, Leon, Elaine P, Lopes, Marta H, Antonangelo, Leila, Medeiros-Ribeiro, Ana C, and Bonfa, Eloisa
- Subjects
RITUXIMAB ,HUMAN research subjects ,IMMUNOGLOBULINS ,CONFIDENCE intervals ,COVID-19 vaccines ,MULTIPLE regression analysis ,MULTIVARIATE analysis ,AUTOIMMUNE diseases ,FISHER exact test ,MANN Whitney U Test ,VACCINE effectiveness ,INFORMED consent (Medical law) ,T-test (Statistics) ,MESSENGER RNA ,DESCRIPTIVE statistics ,RESEARCH funding ,RHEUMATISM ,PREDNISONE ,DATA analysis ,ODDS ratio ,DATA analysis software - Abstract
Objectives To assess immunogenicity of a heterologous fourth dose of an mRNA (BNT162b2) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in autoimmune rheumatic diseases (ARD) patients with poor/non-response to inactivated vaccine (Sinovac-CoronaVac). Methods A total of 164 ARD patients who were coronavirus disease 2019 (COVID-19) poor/non-responders (negative anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies—NAb) to the third dose of Sinovac-CoronaVac received an additional heterologous dose of mRNA (BNT162b2) 3 months after last dose. IgG and NAb were evaluated before and after the fourth dose. Results Significant increases were observed after the fourth dose in IgG (66.4 vs 95.1%, P < 0.001), NAb positivity (5.5 vs 83.5%, P < 0.001) and geometric mean titre (29.5 vs 215.8 AU/ml, P < 0.001), and 28 (17.1%) remained poor/non-responders. Patients with negative IgG after a fourth dose were more frequently under rituximab (P = 0.001). Negative NAb was associated with older age (P = 0.015), RA (P = 0.002), SSc (P = 0.026), LEF (P = 0.016) and rituximab use (P = 0.007). In multiple logistic regression analysis, prednisone dose ≥7.5 mg/day (OR = 0.34; P = 0.047), LEF (OR = 0.32, P = 0.036) and rituximab use (OR = 0.19, P = 0.022) were independently associated with negative NAb after the fourth vaccine dose. Conclusions This is the largest study to provide evidence of a remarkable humoral response after the fourth dose of heterologous mRNA SARS-CoV-2 vaccination in ARD patients with poor/non-response to the third dose of an inactivated vaccine. We further identified that treatment, particularly rituximab and prednisone, impaired antibody response to this additional dose. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov , CoronavRheum #NCT04754698. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
- Author
-
Shinjo, Samuel K, Souza, Fernando H C de, Borges, Isabela B P, Santos, Alexandre M dos, Miossi, Renata, Misse, Rafael G, Medeiros-Ribeiro, Ana C, Saad, Carla G S, Yuki, Emily F N, Pasoto, Sandra G, Kupa, Léonard V K, Ceneviva, Carina, Seraphim, Júlia C, Pedrosa, Tatiana N, Vendramini, Margarete B G, Silva, Clóvis A, Aikawa, Nádia E, and Bonfá, Eloisa
- Subjects
- *
AUTOIMMUNE disease prevention , *MUSCLE diseases , *COVID-19 , *CLINICAL trials , *IMMUNOGLOBULINS , *CONFIDENCE intervals , *COVID-19 vaccines , *IMMUNOCOMPROMISED patients , *SEROCONVERSION , *IMMUNOSUPPRESSION , *SYMPTOMS , *DESCRIPTIVE statistics , *PATIENT safety , *LONGITUDINAL method , *COMORBIDITY - Abstract
Objectives To evaluate immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in systemic autoimmune myopathies (SAMs) and the possible influence of baseline disease parameters, comorbidities and therapy on immune response. Methods This prospective controlled study included 53 patients with SAMs and 106 non-immunocompromised control group (CTRL). All participants received two doses of the Sinovac-CoronaVac vaccine (28-day interval). Immunogenicity was assessed by anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC), anti-S1/S2 IgG geometric mean titre (GMT), factor increase GMT (FI-GMT), neutralizing antibodies (NAb) positivity, and median neutralizing activity after each vaccine dose (D0 and D28) and six weeks after the second dose (D69). Participants with pre-vaccination positive IgG serology and/or NAb and those with RT-PCR confirmed COVID-19 during the protocol were excluded from immunogenicity analysis. Results Patients and CTRL had comparable sex (P> 0.99) and age (P= 0.90). Immunogenicity of 37 patients and 79 CTRL-naïve participants revealed at D69, a moderate but significantly lower SC (64.9% vs 91.1%, P< 0.001), GMT [7.9 (95%CI 4.7–13.2) vs 24.7 (95%CI 30.0–30.5) UA/ml, P< 0.001] and frequency of NAb (51.4% vs 77.2%, P< 0.001) in SAMs compared with CTRL. Median neutralizing activity was comparable in both groups [57.2% (interquartile range (IQR) 43.4–83.4) vs 63.0% (IQR 40.3–80.7), P= 0.808]. Immunosuppressives were less frequently used among NAb+ patients vs NAb- patients (73.7% vs 100%, P= 0.046). Type of SAMs, disease status, other drugs or comorbidities did not influence immunogenicity. Vaccine-related adverse events were mild with similar frequencies in patients and CTRL (P> 0.05). Conclusion Sinovac-CoronaVac is safe and has a moderate short-term immunogenicity in SAMs, but reduced compared with CTRL. We further identified that immunosuppression is associated with diminished NAb positivity. Trial registration COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS (CoronavRheum), http://clinicaltrials.gov/ct2/show/NCT04754698 [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis.
- Author
-
Hoff, Leonardo S, Souza, Fernando H C de, Miossi, Renata, and Shinjo, Samuel K
- Subjects
THERAPEUTIC use of immunoglobulins ,METHYLPREDNISOLONE ,INTRAVENOUS therapy ,DERMATOMYOSITIS ,POLYMYOSITIS ,CONFIDENCE intervals ,TIME ,MULTIVARIATE analysis ,RETROSPECTIVE studies ,AUTOIMMUNE diseases ,TREATMENT effectiveness ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,MYOSITIS ,DATA analysis software ,LONGITUDINAL method ,PROPORTIONAL hazards models - Abstract
Objective To evaluate the long-term effects of pulse i.v. methylprednisolone (IVMP) or IVIG administered during the first year of diagnosis in DM and PM patients. Methods This is a retrospective single-centre cohort study of patients with PM/DM followed for up to 4 years from 2001 to 2017. We used Cox regression models to estimate hazard ratios (HRs) and assess the effects of early pulse IVMP or IVIG on three outcomes: complete clinical response, CS discontinuation, and survival. Analysis was adjusted for clinical, laboratory and treatment covariates. Results A total of 204 patients were included and categorized into four initial treatment groups: pulse IVMP (n = 46), pulse IVMP + IVIG (n = 55), IVIG (n = 10), and without IVMP or IVIG (n = 93). The groups of early pulse IVMP and pulse IVMP + IVIG had a higher HR for complete clinical response in the multivariate models (HR = 1.56, 95% CI: 1.05, 2.33, P = 0.029; and HR = 1.58, 95% CI: 1.02, 2.45, P = 0.041, respectively). Only the group of pulse IVMP + IVIG had a significant association with CS discontinuation in the multivariate analysis (HR = 1.65, 95% CI: 1.02, 2.68, P = 0.043). Early pulse IVMP or IVIG had no impact on mortality. Conclusion Despite having a more severe disease profile, patients with PM/DM submitted to pulse IVMP or pulse IVMP + IVIG during the first year of diagnosis had a higher HR for complete clinical response, whereas the combination of pulse IVMP + IVIG had an association with CS discontinuation. Prospective long-term studies are warranted to confirm these benefits of early pulse IVMP and IVIG on patients with PM/DM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients.
- Author
-
Gualano, Bruno, Saad, Carla G. S., Sieczkowska, Sofia M., Lemes, Ítalo Ribeiro, Silva, Rafael Pires da, Pinto, Ana J., Mazzolani, Bruna C., Smaira, Fabiana I., Gil, Saulo, Oliveira-Junior, Gersiel, Aikawa, Nadia E., Medeiros-Ribeiro, Ana C., Silva, Clovis A., Yuki, Emily F. N., Pasoto, Sandra G., Pereira, Rosa Maria R., Shinjo, Samuel K., Andrade, Danieli C. O., Sampaio-Barros, Percival D., and Roschel, Hamilton
- Subjects
COVID-19 vaccines ,BOOSTER vaccines ,IMMUNE response ,IMMUNOCOMPROMISED patients ,SPONDYLOARTHROPATHIES - Abstract
This randomized controlled study aimed to investigate whether a single bout of exercise before the homologous booster dose of a SARS-CoV-2 inactivated vaccine could enhance immunogenicity in patients with spondyloarthritis. We selected 60 consecutive patients with spondyloarthritis (SpA). Patients assigned to the intervention group performed an exercise bout comprising three exercises. Then, they remained at rest for 1 h before vaccination. The control group remained at rest before vaccination. Immunogenicity was assessed before (Pre) and 1 mo after (Post) the booster using seropositivity rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), frequency of neutralizing antibodies (NAb) positivity, and NAb activity. At Pre, 16 patients from the exercise group and 16 patients from the control group exhibited seropositivity for IgG (59% vs. 57.1%), and 1 mo after the booster dose, seropositivity occurred in 96% versus 100% of the cases. Only 10 patients from the exercise group and 12 patients from the control group showed positive NAb serology at Pre (37% vs. 42.8%). One month following the booster, NAb positivity was 96% versus 93%. GMT was comparable between groups at Pre. At Post, GMT increased similarly in both groups. Likewise, NAb activity was similar between groups at Pre and increased similarly in both of them as a result of the booster (47.5% vs. 39.9%). In conclusion, a single bout of exercise did not enhance immunogenicity to a homologous booster dose of an inactivated SARS-CoV-2 vaccine among patients with spondyloarthritis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis
- Author
-
Shinjo, Samuel K., Pereira, Rosa M. R., Tizziani, Vivian A. P., Radu, Ari S., and Levy-Neto, Maurício
- Published
- 2007
- Full Text
- View/download PDF
19. Chloroquine-induced bull’s eye maculopathy in rheumatoid arthritis: related to disease duration?
- Author
-
Shinjo, Samuel K., Maia Júnior, Otacílio O., Tizziani, Vivian A. P., Morita, Celso, Kochen, Jussara A. L., Takahashi, Walter Y., and Laurindo, Ieda M. M.
- Published
- 2007
- Full Text
- View/download PDF
20. Significant association between PTPN11 polymorphism and gastric atrophy among Japanese Brazilians
- Author
-
Kawai, Sayo, Goto, Yasuyuki, Ito, Lucy S., Oba-Shinjo, Sueli M., Uno, Miyuki, Shinjo, Samuel K., Marie, Suely K.N., Ishida, Yoshiko, Nishio, Kazuko, Naito, Mariko, and Hamajima, Nobuyuki
- Published
- 2006
- Full Text
- View/download PDF
21. Community-based familial study of Helicobacter pylori infection among healthy Japanese Brazilians
- Author
-
Ito, Lucy S., Oba-Shinjo, Sueli M., Shinjo, Samuel K., Uno, Miyuki, Marie, Suely K.N., and Hamajima, Nobuyuki
- Published
- 2006
- Full Text
- View/download PDF
22. Lifestyle factors associated with atrophic gastritis among Helicobacter pylori-seropositive Japanese-Brazilians in SÃo Paulo
- Author
-
Ito, Lucy S., Oba-Shinjo, Sueli M., Marie, Suely K. N., Uno, Miyuki, Shinjo, Samuel K., Hamajima, Nobuyuki, Tajima, Kazuo, and Tominaga, Suketami
- Published
- 2003
- Full Text
- View/download PDF
23. A randomized clinical trial on the effects of exercise on muscle remodelling following bariatric surgery.
- Author
-
Gil, Saulo, Kirwan, John P., Murai, Igor H., Dantas, Wagner S., Merege‐Filho, Carlos Alberto Abujabra, Ghosh, Sujoy, Shinjo, Samuel K., Pereira, Rosa M.R., Teodoro, Walcy R., Felau, Sheylla M., Benatti, Fabiana B., de Sá‐Pinto, Ana L., Lima, Fernanda, de Cleva, Roberto, Santo, Marco Aurélio, Gualano, Bruno, and Roschel, Hamilton
- Subjects
BARIATRIC surgery ,MORBID obesity ,CLINICAL trials ,MUSCLE strength ,AEROBIC exercises ,ACTIVE recovery ,EXERCISE therapy - Abstract
Background: Muscle atrophy and strength loss are common adverse outcomes following bariatric surgery. This randomized, controlled trial investigated the effects of exercise training on bariatric surgery‐induced loss of muscle mass and function. Additionally, we investigated the effects of the intervention on molecular and histological mediators of muscle remodelling. Methods: Eighty women with obesity were randomly assigned to a Roux‐en‐Y gastric bypass (RYGB: n = 40, age = 42 ± 8 years) or RYGB plus exercise training group (RYGB + ET: n = 40, age = 38 ± 7 years). Clinical and laboratory parameters were assessed at baseline, and 3 (POST3) and 9 months (POST9) after surgery. The 6 month, three‐times‐a‐week, exercise intervention (resistance plus aerobic exercise) was initiated 3 months post‐surgery (for RYGB + ET). A healthy, lean, age‐matched control group was recruited to provide reference values for selected variables. Results: Surgery resulted in a similar (P = 0.66) reduction in lower‐limb muscle strength in RYGB and RYGB+ET (−26% vs. −31%), which was rescued to baseline values in RYGB + ET (P = 0.21 vs. baseline) but not in RYGB (P < 0.01 vs. baseline). Patients in RYGB+ET had greater absolute (214 vs. 120 kg, P < 0.01) and relative (2.4 vs. 1.4 kg/body mass, P < 0.01) muscle strength compared with RYGB alone at POST9. Exercise resulted in better performance in timed‐up‐and‐go (6.3 vs. 7.1 s, P = 0.05) and timed‐stand‐test (18 vs. 14 repetitions, P < 0.01) compared with RYGB. Fat‐free mass was lower (POST9‐PRE) after RYBG than RYGB + ET (total: −7.9 vs. −4.9 kg, P < 0.01; lower‐limb: −3.8 vs. −2.7 kg, P = 0.02). Surgery reduced Types I (~ − 21%; P = 0.99 between‐group comparison) and II fibre cross‐sectional areas (~ − 27%; P = 0.88 between‐group comparison), which were rescued to baseline values in RYGB+ET (P > 0.05 vs. baseline) but not RYGB (P > 0.01 vs. baseline). RYGB + ET showed greater Type I (5187 vs. 3898 μm2, P < 0.01) and Type II (5165 vs. 3565 μm2, P < 0.01) fCSA than RYGB at POST9. RYGB + ET also resulted in increased capillarization (P < 0.01) and satellite cell content (P < 0.01) than RYGB at POST9. Gene‐set normalized enrichment scores for the muscle transcriptome revealed that the ubiquitin‐mediated proteolysis pathway was suppressed in RYGB + ET at POST9 vs. PRE (NES: −1.7; P < 0.01), but not in RYGB. Atrogin‐1 gene expression was lower in RYGB + ET vs. RYGB at POST9 (0.18 vs. 0.71‐fold change, P < 0.01). From both genotypic and phenotypic perspectives, the muscle of exercised patients resembled that of healthy lean individuals. Conclusions: This study provides compelling evidence—from gene to function—that strongly supports the incorporation of exercise into the recovery algorithm for bariatric patients so as to counteract the post‐surgical loss of muscle mass and function. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Acute cardiometabolic effects of brief active breaks in sitting for patients with rheumatoid arthritis.
- Author
-
Pinto, Ana J., Meireles, Kamila, Peçanha, Tiago, Mazzolani, Bruna C., Smaira, Fabiana I., Rezende, Diego, Benatti, Fabiana B., Ribeiro, Ana C. M., Pinto, Ana L. S., Lima, Fernanda R., Shinjo, Samuel K., Dantas, Wagner S., Mellett, Natalie A., Meikle, Peter J., Owen, Neville, Dunstan, David W., Roschel, Hamilton, and Gualano, Bruno
- Subjects
RHEUMATOID arthritis ,SYSTOLIC blood pressure ,BRASSINOSTEROIDS ,BLOOD pressure ,CHYLOMICRONS - Abstract
Exercise is a treatment in rheumatoid arthritis, but participation in moderate-to-vigorous exercise is challenging for some patients. Light-intensity breaks in sitting could be a promising alternative. We compared the acute effects of active breaks in sitting with those of moderate-to-vigorous exercise on cardiometabolic risk markers in patients with rheumatoid arthritis. In a crossover fashion, 15 women with rheumatoid arthritis underwent three 8-h experimental conditions: prolonged sitting (SIT), 30-min bout of moderate-to-vigorous exercise followed by prolonged sitting (EX), and 3-min bouts of light-intensity walking every 30 min of sitting (BR). Postprandial glucose, insulin, c-peptide, triglycerides, cytokines, lipid classes/subclasses (lipidomics), and blood pressure responses were assessed. Muscle biopsies were collected following each session to assess targeted proteins/genes. Glucose [-28% in area under the curve (AUC), P = 0.036], insulin (-28% in AUC, P = 0.016), and c-peptide (-27% in AUC, P = 0.006) postprandial responses were attenuated in BR versus SIT, whereas only c-peptide was lower in EX versus SIT (-20% in AUC, P = 0.002). IL-1b decreased during BR, but increased during EX and SIT (P = 0.027 and P = 0.085, respectively). IL-1ra was increased during EX versus BR (P = 0.002). TNF-α concentrations decreased during BR versus EX (P = 0.022). EX, but not BR, reduced systolic blood pressure (P = 0.013). Lipidomic analysis showed that 7 of 36 lipid classes/subclasses were significantly different between conditions, with greater changes being observed in EX. No differences were observed for protein/gene expression. Brief active breaks in sitting can offset markers of cardiometabolic disturbance, which may be particularly useful for patients who may find it difficult to adhere to exercise. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. New insights on the specificity of heparin and heparan sulfate lyases from Flavobacterium heparinum revealed by the use of synthetic derivatives of K5 polysaccharide from E. coli. and 2-O-desulfated heparin
- Author
-
Nader, Helena B., Kobayashi, Elsa Y., Chavante, Suely F., Tersariol, Ivarne L.S., Castro, Ricardo A.B., Shinjo, Samuel K., Naggi, A., Torri, Giangiacomo, Casu, Benito, and Dietrich, Carl P.
- Published
- 1999
- Full Text
- View/download PDF
26. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
- Author
-
Saad, Carla G S, Borba, Eduardo F, Aikawa, Nadia E, Silva, Clovis A, Pereira, Rosa M R, Calich, Ana Luisa, Moraes, Julio C B, Ribeiro, Ana C M, Viana, Vilma S T, Pasoto, Sandra G, Carvalho, Jozelio F, França, Ivan L A, Guedes, Lissiane K N, Shinjo, Samuel K, Sampaio-Barros, Percival D, Caleiro, Maria T, Goncalves, Celio R, Fuller, Ricardo, Levy-Neto, Mauricio, Timenetsky, Maria Carmo S, Precioso, Alexander R, and Bonfa, Eloisa
- Published
- 2011
- Full Text
- View/download PDF
27. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort
- Author
-
Shinjo, Samuel K., Bonfá, Eloísa, Wojdyla, Daniel, Borba, Eduardo F., Ramirez, Luis A., Scherbarth, Hugo R., Brenol, João C. Tavares, Chacón-Diaz, Rosa, Neira, Oscar J., Berbotto, Guillermo A., de la Torre, Ignacio Garcia, Acevedo-Vázquez, Eduardo M., Massardo, Loreto, Barile-Fabris, Leonor A., Caeiro, Francisco, Silveira, Luis H., Sato, Emilia I., Buliubasich, Sandra, Alarcón, Graciela S., and Pons-Estel, Bernardo A.
- Published
- 2010
- Full Text
- View/download PDF
28. Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: Bimodal Pattern of Onset and Treatment Response.
- Author
-
Fargetti, Simone, Ugolini-Lopes, Michelle R., Pasoto, Sandra G., Seguro, Luciana P. C., Shinjo, Samuel K., Bonfa, Eloisa, and Borba, Eduardo F.
- Published
- 2021
- Full Text
- View/download PDF
29. Exercise-Induced Increases in Insulin Sensitivity After Bariatric Surgery Are Mediated By Muscle Extracellular Matrix Remodeling.
- Author
-
Dantas, Wagner S., Roschel, Hamilton, Murai, Igor H., Gil, Saulo, Davuluri, Gangarao, Axelrod, Christopher L., Ghosh, Sujoy, Newman, Susan S., Zhang, Hui, Shinjo, Samuel K., das Neves, Willian, Merege-Filho, Carlos, Teodoro, Walcy R., Capelozzi, Vera L., Pereira, Rosa Maria, Benatti, Fabiana B., de Sá-Pinto, Ana L., de Cleva, Roberto, Santo, Marco A., and Kirwan, John P.
- Subjects
INSULIN sensitivity ,GLUCOSE tolerance tests ,BARIATRIC surgery ,EXTRACELLULAR matrix ,AEROBIC exercises ,ISOMETRIC exercise ,RESEARCH ,SKELETAL muscle ,WESTERN immunoblotting ,ANIMAL experimentation ,RESEARCH methodology ,PHYSICAL fitness ,EVALUATION research ,MEDICAL cooperation ,BIOINFORMATICS ,COMPARATIVE studies ,STEM cells ,RESEARCH funding ,GASTRIC bypass ,EXTRACELLULAR space ,CELL lines ,POLYMERASE chain reaction ,INSULIN resistance ,MICE - Abstract
Exercise seems to enhance the beneficial effect of bariatric (Roux-en-Y gastric bypass [RYGB]) surgery on insulin resistance. We hypothesized that skeletal muscle extracellular matrix (ECM) remodeling may underlie these benefits. Women were randomized to either a combined aerobic and resistance exercise training program following RYGB (RYGB + ET) or standard of care (RYGB). Insulin sensitivity was assessed by oral glucose tolerance test. Muscle biopsy specimens were obtained at baseline and 3 and 9 months after surgery and subjected to comprehensive phenotyping, transcriptome profiling, molecular pathway identification, and validation in vitro. Exercise training improved insulin sensitivity beyond surgery alone (e.g., Matsuda index: RYGB 123% vs. RYGB + ET 325%; P ≤ 0.0001). ECM remodeling was reduced by surgery alone, with an additive benefit of surgery and exercise training (e.g., collagen I: RYGB -41% vs. RYGB + ET -76%; P ≤ 0.0001). Exercise and RYGB had an additive effect on enhancing insulin sensitivity, but surgery alone did not resolve insulin resistance and ECM remodeling. We identified candidates modulated by exercise training that may become therapeutic targets for treating insulin resistance, in particular, the transforming growth factor-β1/SMAD 2/3 pathway and its antagonist follistatin. Exercise-induced increases in insulin sensitivity after bariatric surgery are at least partially mediated by muscle ECM remodeling. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. Distribution and composition of glycosaminoglycans in the left human coronary arterial branches under myocardial bridge
- Author
-
Shinjo, Samuel K., Prates, Nadir E.V.B., Oba, Sueli M., Sampaio, Lúcia O., and Nader, Helena B.
- Published
- 1999
- Full Text
- View/download PDF
31. Increased Insulin Resistance and Glucagon Levels in Mild/Inactive Systemic Lupus Erythematosus Patients Despite Normal Glucose Tolerance.
- Author
-
Miyake, Cíntia N. H., Gualano, Bruno, Dantas, Wagner S., Pereira, Renato T., Neves, William, Zambelli, Vanessa O., Shinjo, Samuel K., Pereira, Rosa M., Silva, Elizabeth R., Sá-Pinto, Ana Lúcia, Borba, Eduardo, Roschel, Hamilton, Bonfá, Eloisa, Benatti, Fabiana B., Miyake, Cíntia N H, Sá-Pinto, Ana Lúcia, and Bonfá, Eloisa
- Subjects
SYSTEMIC lupus erythematosus diagnosis ,BLOOD sugar ,CARRIER proteins ,COMPARATIVE studies ,FASTING ,GLUCAGON ,GLUCOSE tolerance tests ,INGESTION ,INSULIN ,INSULIN resistance ,ISLANDS of Langerhans ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,SYSTEMIC lupus erythematosus ,EVALUATION research ,CROSS-sectional method ,SEVERITY of illness index ,CASE-control method ,SKELETAL muscle - Abstract
Objective: To assess insulin sensitivity in patients with systemic lupus erythematosus (SLE) in response to a meal tolerance test (MTT).Methods: In this cross-sectional study, 33 adult females with mild/inactive SLE (SLE group) and 16 age- and body mass index-matched female healthy controls (CTRL group) underwent an MTT and were assessed for insulin sensitivity and beta cell function. Skeletal muscle protein expressions of total and membrane insulin-dependent glucose transporter 4 (GLUT-4) were also evaluated (SLE group: n = 10, CTRL group: n = 5); muscle biopsies were performed after MTT. Further measurements included inflammatory cytokines, adipocytokines, physical activity level, body composition, and food intake.Results: SLE and CTRL groups showed similar fasting glucose, glucose response, and skeletal muscle GLUT-4 translocation after MTT. However, the SLE group demonstrated higher fasting insulin levels (P = 0.01; effect size [ES] 1.2), homeostatic model assessment insulin resistance (IR) (P = 0.03; ES 1.1), insulin-to-glucose ratio response to MTT (P = 0.02; ES 1.2), fasting glucagon levels (P = 0.002; ES 2.7), glucagon response to MTT (P = 0.0001; ES 2.6), and a tendency toward lower Matsuda index of whole-body insulin sensitivity (P = 0.06; ES -0.5) when compared with the CTRL group. Fasting proinsulin-to-insulin ratio and proinsulin-to-insulin ratio response to MTT were similar between groups (P > 0.05), while the SLE group showed a higher insulinogenic index when compared with the CTRL group (P = 0.02; ES = 0.9).Conclusion: We have identified that SLE patients had a bi-hormone metabolic abnormality characterized by increased IR and hyperglucagonemia despite normal glucose tolerance and preserved beta cell function and skeletal muscle GLUT-4 translocation. Strategies capable of ameliorating insulin sensitivity to reduce the risk of type 2 diabetes mellitus and cardiovascular disease in SLE may require more than targeting IR alone. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
32. Exercise in Takayasu Arteritis: Effects on Inflammatory and Angiogenic Factors and Disease-Related Symptoms.
- Author
-
Oliveira, Diego S., Shinjo, Samuel K., Silva, Marilda G., de Sá-Pinto, Ana L., Lima, Fernanda R., Roschel, Hamilton, Mello, Suzana B. V., Costa-Hong, Valéria, Irigoyen, Maria C. C., Pereira, Rosa M., Gualano, Bruno, de Sá-Pinto, Ana L, and Costa-Hong, Valéria
- Subjects
EXERCISE ,EXERCISE tests ,INFLAMMATORY mediators ,LONGITUDINAL method ,TREATMENT effectiveness ,PATHOLOGIC neovascularization ,TAKAYASU arteritis ,THERAPEUTICS - Abstract
Objective: To investigate the effects of acute and chronic exercise in female patients with remissive Takayasu arteritis (TAK).Methods: This was a 2-part prospective study. In study 1, cytokines and soluble tumor necrosis factor (TNF) receptors were assessed at rest and every 60 minutes during a 3-hour recovery period following an acute exercise session in TAK (n = 11) and heathy control (n = 10) groups. In study 2, a subsample from the TAK group (n = 6) underwent a 12-week exercise training program. Before and after training, the acute session of aerobic exercise was performed and cytokines and soluble TNF receptors were assessed at the same time points described above. Muscle function, strength, aerobic capacity, endothelial function, quality of life, and walking impairment scores were evaluated.Results: In study 1, the acute session of aerobic exercise led to overall similar responses on cytokine kinetics in the TAK and heathy control groups. In study 2, the exercise training program did not exacerbate inflammatory cytokines in TAK patients, while the proinflammatory cytokine TNF was diminished both at rest and following the acute session of aerobic exercise. In addition, the exercise training program increased the pro-angiogenic factors vascular endothelial growth factor (at rest) and platelet-derived growth factor AA (at rest and in response to the acute session of aerobic exercise). The exercise training program improved muscle strength and function, whereas aerobic capacity, quality of life, and endothelial function parameters remained unchanged.Conclusion: Exercise could be a well-tolerated, safe, and effective intervention able to induce immunomodulatory and pro-angiogenic effects and to increase strength and function in patients with TAK. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
33. Thrombosis of Atypical Location at Lupus Onset.
- Author
-
Macêdo, Marina B. and Shinjo, Samuel K.
- Published
- 2022
- Full Text
- View/download PDF
34. On the catalytic mechanism of polysaccharide lyases: evidence of His and Tyr involvement in heparin lysis by heparinase I and the role of Ca2+.
- Author
-
Córdula, Carolina R., Lima, Marcelo A., Shinjo, Samuel K., Gesteira, Tarsis F., Pol-Fachin, Laércio, Coulson-Thomas, Vivien J., Verli, Hugo, Yates, Edwin A., Rudd, Timothy R., Pinhal, Maria A. S., Toma, Leny, Dietrich, Carl P., Nader, Helena B., and Tersariol, Ivarne L. S.
- Published
- 2014
- Full Text
- View/download PDF
35. Helicobacter pylori Seropositivity among 963 Japanese Brazilians According to Sex, Age, Generation, and Lifestyle Factors.
- Author
-
Ito, Lucy S., Oba, Sueli M., Hamajima, Nobuyuki, Marie, Suely K. N., Uno, Miyuki, Shinjo, Samuel K., Kino, Aya, Lavilla, Flávia, Inoue, Manami, Tajima, Kazuo, and Tominaga, Suketami
- Published
- 2001
- Full Text
- View/download PDF
36. Erratum. Exercise-Induced Increases in Insulin Sensitivity After Bariatric Surgery Are Mediated By Muscle Extracellular Matrix Remodeling. Diabetes 2020;69:1675-1691.
- Author
-
Dantas, Wagner S., Roschel, Hamilton, Murai, Igor H., Gil, Saulo, Davuluri, Gangarao, Axelrod, Christopher L., Ghosh, Sujoy, Newman, Susan S., Zhang, Hui, Shinjo, Samuel K., das Neves, Willian, Merege-Filho, Carlos, Teodoro, Walcy R., Capelozzi, Vera L., Pereira, Rosa Maria, Benatti, Fabiana B., de Sá-Pinto, Ana L., de Cleva, Roberto, Santo, Marco A., and Kirwan, John P.
- Subjects
INSULIN sensitivity ,BARIATRIC surgery ,EXTRACELLULAR matrix ,DIABETES - Published
- 2021
- Full Text
- View/download PDF
37. Neuromodulation with aerobic exercise reduces fatigue in systemic lupus erythematosus: a randomised, sham-controlled, double-blind study.
- Author
-
de Andrade VP, Dos Santos AM, Seguro LPC, Yuki EFN, Lopes MRU, Grecco MV, Borba EF, Greve JMA, and Shinjo SK
- Subjects
- Humans, Double-Blind Method, Female, Adult, Middle Aged, Treatment Outcome, Exercise Therapy methods, Exercise, Severity of Illness Index, Time Factors, Sleep Quality, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic therapy, Lupus Erythematosus, Systemic physiopathology, Lupus Erythematosus, Systemic diagnosis, Fatigue etiology, Fatigue therapy, Fatigue physiopathology, Transcranial Direct Current Stimulation
- Abstract
Objectives: Transcranial direct current stimulation (tDCS) combined with aerobic exercise (tDCS-AE) effectively reduces fatigue in patients with fibromyalgia. However, no study has assessed this method in systemic lupus erythematosus (SLE) patients with significant fatigue. Therefore, we evaluated the safety and efficacy of tDCS-AE for significant fatigue symptoms in adult female SLE patients., Methods: This randomised, sham-controlled, double-blind study included 25 patients with SLE in remission or low disease activity (SLEDAI-2K £4) and with significant fatigue [≥36 points on the Fatigue Severity Scale (FSS) or ≥38 points on the Modified Fatigue Scale (MFIS)]. The patients received sham or tDCS for five consecutive days. The anode and cathode were positioned at M1 and Fp2, respectively (international 10-20 EEG system). tDCS was applied at an intensity of 2mA, and density of 0.057mA/cm2 in the tDCS-AE group. Both groups underwent combined low-intensity treadmill exercise. FSS, MFIS, pain visual analogue scale, physical activity, and sleep quality were evaluated at baseline and on days 7, 30, and 60. Adherence and safety were assessed using a standardised questionnaire., Results: Improvement in fatigue levels was observed in both groups. However, a sustained reduction in fatigue levels on days 30 and 60 occurred only with tDCS-AEs (p<0.05). No significant differences were observed in pain level, sleep quality, or physical activity. No disease flares occurred and the adverse effects were mild and transient. Finally, the patient's adherence to the treatment was satisfactory., Conclusions: Despite isolated AEs, there was an improvement in fatigue, however, only tDCS-AE maintained significant and sustained improvement.
- Published
- 2024
- Full Text
- View/download PDF
38. Anti-Ha Antisynthetase Syndrome: A Case Report.
- Author
-
De Andrade VP, Miossi R, De Souza FH, and Shinjo SK
- Abstract
Anti-synthetase syndrome (ASyS) is a rare systemic autoimmune myopathy characterized by the involvement of muscles, lungs, and joints, in addition to Raynaud's phenomenon, "mechanics' hand," and fever. Laboratory ASyS is defined by the positivity of anti-aminoacyl-tRNA synthetase autoantibodies, of which anti-Jo-1 is the most common. Herein, we reported an ASyS defined by an anti-Ha autoantibody, which has rarely been described in the literature. Moreover, to the best of our knowledge, we reported the first case of anti-Ha ASyS in Brazil., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, De Andrade et al.)
- Published
- 2024
- Full Text
- View/download PDF
39. Association Between Wearable Device Use and Quality of Life in Patients With Idiopathic Inflammatory Myopathies and Primary Systemic Vasculitis.
- Author
-
Pereira NG, Dos Santos AM, and Shinjo SK
- Abstract
Background Despite the increasing use of wearable devices worldwide, concise data on these instruments in patients with systemic autoimmune rheumatic diseases, including idiopathic inflammatory myopathies (IIM) and primary systemic vasculitis (PSV), are lacking. Objectives The aim of this study is to investigate the knowledge and use of wearable devices and to assess their impact on the general quality of life of patients with IIM and PSV. Moreover, we compared these characteristics between patients with IIM and PSV users and non-users of wearable devices. Methods This single-center, cross-sectional study was conducted between January 2023 and June 2023. We included adult patients with IIM and PSV and a control group (CTR) and evaluated their use of cell phones and wearables, level of physical activity, and quality of life. Results A total of 132 patients with IIM, 82 with PSV, and 178 in the CTR were evaluated. Overall, 169 patients and 144 in the CTR were aware of wearable devices, of whom 50 (29.6%) and 47 (32.6%), respectively, had already used this technology. In addition, the IPAQ-Mets and EQ-5D scores were lower in the IIM and PSV groups than in the CTR, and the fatigue severity scale (FSS) scores were higher in the IIM and PSV groups than in the CTR. Patients who used the devices showed FSS scores of 29 (18-40) points, with higher levels of IPAQ-Mets among device users, indicating greater physical activity than among nonusers. Conclusion Based on the results, the use of wearable devices is associated with better fatigue and IPAQ scores. Possibly, the use of such devices can have an impact on better lifestyle habits among these patients., Competing Interests: The authors have declared financial relationships, which are detailed in the next section., (Copyright © 2024, Pereira et al.)
- Published
- 2024
- Full Text
- View/download PDF
40. Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review.
- Author
-
Saygin D, Glaubitz S, Zeng R, Bottai M, de Visser M, Dimachkie MM, Fiorentino D, Gerhardson I, Kuwana M, Miller FW, Needham M, Rider LG, Salem Y, Schlüter S, Shinjo SK, Wang G, Werth VP, Aggarwal R, and Lundberg IE
- Abstract
The 2017 EULAR/ACR classification criteria for adult/juvenile idiopathic inflammatory myopathies (IIM) were established using a data-driven approach by an international group of myositis experts to allow classification of IIM and its major subtypes. Since their publication, the performance of the criteria has been tested in multiple cohorts worldwide and significant limitations have been identified. Moreover, the understanding and classification of IIM have evolved since 2017. This scoping review was undertaken as part of a large international project to revise the EULAR/ACR criteria and aims to i) summarise the evidence from the current literature on the performance characteristics of the 2017 EULAR/ACR classification criteria in various cohorts and IIM subtypes, and ii) delineate the factors that need to be considered in the revision of the classification criteria. A systematic search of Medline (via PubMed), Cumulative Index to Nursing and Allied Health Literature, and conference abstract archives was conducted independently by three investigators for studies on the EULAR/ACR criteria published between October 2017 and January 2023. This scoping review of 19 articles and 13 abstracts revealed overall good performance characteristics of the EULAR/ACR criteria for IIM, yet deficiencies in lack of inclusion of certain IIM subtypes, such as immune mediated necrotising myopathy, amyopathic dermatomyositis, antisynthetase syndrome and overlap myositis. Published modifications that may improve the performance characteristics of the criteria for classification of IIM subtypes were also summarised. The results of this review suggest that a revision of the EULAR/ACR criteria is warranted.
- Published
- 2024
- Full Text
- View/download PDF
41. Transcranial Direct Current Stimulation Is Safe and Reduces Chronic Fatigue in Patients With Stable Systemic Lupus Erythematosus and Rheumatoid Arthritis.
- Author
-
De Andrade VP, Dos Santos AM, and Shinjo SK
- Abstract
To the best of our knowledge, this is the first case series to assess a combined technique of transcranial direct current stimulation (tDCS - a non-pharmacological and non-invasive brain stimulation) and aerobic exercise in one patient with systemic lupus erythematosus (SLE) and another with rheumatoid arthritis (RA) and significant chronic fatigue. We conducted five sessions of tDCS combined with low-intensity treadmill exercise. Fatigue levels were assessed using the Fatigue Severity Scale and the Visual Analog Scale for fatigue before (pre), immediately after five tDCS sessions (post-zero), and after six months (post-6-mo). The level of fatigue decreased, and functionality improved significantly post-zero and remained sustainable post-6-mo in both SLE and RA cases. There was only one mild and transient side effect (headache) specifically in the patient with RA, and no disease reactivation occurred in any of the cases. Our data showed that tDCS combined with aerobic exercise appears to be safe and promising for reducing fatigue and improving functionality in patients with SLE and RA. Randomized studies with larger sample sizes are required to corroborate our findings., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, De Andrade et al.)
- Published
- 2024
- Full Text
- View/download PDF
42. Transcranial direct current stimulation is safe and effective in autoimmune myopathies: a randomised, double-blind, sham-controlled trial.
- Author
-
de Sousa LFA, Missé RG, Dos Santos LM, Tanaka C, Greve JMA, Baptista AF, and Shinjo SK
- Subjects
- Humans, Prospective Studies, Double-Blind Method, Emotions, Transcranial Direct Current Stimulation adverse effects, Transcranial Direct Current Stimulation methods, Muscular Diseases
- Abstract
Objectives: We aimed to assess the safety and efficacy of transcranial direct current stimulation (tDCS) in patients with systemic autoimmune myopathies (SAMs)., Methods: This prospective, randomised, sham-controlled, double-blind, study included 20 patients with SAMs allocated to receive sham or active tDCS (2mA, 20 minutes, 3 days). Electrodes were positioned with the anode over the C1 or C2, whereas the cathode was placed over the Fp2 or Fp1, respectively. The groups were evaluated in four periods with specific questionnaires and functional tests: pre-stimulation and after 30 minutes, three weeks, and eight weeks post-tDCS., Results: Two patients from the sham group withdrew after the three sessions. The demographic data, type of myositis, disease duration, and disease status were comparable between the active and sham tDCS groups. After interventions, in the active tDCS group, the physical aspects of SF-36 in week eight, mean and better timed up-and-go test at each evaluation, peak torque of stimulated inferior limb extension improved significantly (p<0.05). The emotional aspect of SF-36 decreased only in the active tDCS group (p<0.001). The patients' adherence to the protocol was 100% and no serious adverse event was reported, including disease relapses., Conclusions: This study evidences the safety of tDCS, as well as its potential efficacy in improving muscle strength and function in SAMs patients. More studies with a larger sample and longer tDCS sessions are necessary to corroborate the results of the present study.
- Published
- 2023
- Full Text
- View/download PDF
43. High prevalence of necrotising myopathy pattern in muscle biopsies of patients with anti-Jo-1 antisynthetase syndrome.
- Author
-
da Silva LMB, Borges IBP, and Shinjo SK
- Subjects
- Humans, Female, Prevalence, Muscles pathology, Biopsy, Necrosis, Autoantibodies, Myositis diagnosis, Muscular Diseases diagnosis
- Abstract
Objectives: Until now, researchers have not provided a well-defined muscle histological pattern for antisynthetase syndrome (ASSD). Therefore, we aimed to analyse the muscle biopsies of patients with anti-Jo-1 ASSD., Methods: This study included 26 patients with anti-Jo-1 ASSD admitted for investigation of the disease and obligatorily with muscle impairment, from 2010 to 2021, whose serial frozen muscle sections were analysed., Results: Patients' mean age at disease diagnosis was 42.8±11.6 years, and the female gender was most predominant. Concerning muscle biopsies, cell infiltrates were present in 76.9% of the samples, and they were mainly located at the endomysium area (70%), with a predominance of macrophages (92.9%). Fiber muscle necrosis was present in 92.3% and was diffused in 54.2%. Expression of MHC-I was seen in all samples. Samples were mostly marked by the presence of CD68+ and discreet/low CD4+ and CD8+ staining, which is consistent with a higher predominance of observed necrosis and macrophage cell infiltrates. In general, 38.5% of patients had a necrotising myopathy pattern in muscle biopsies, whereas 34.6% and 26.9% had a general inflammatory myopathy pattern and nonspecific myopathy, respectively. This necrotising myopathy pattern was not associated with the demographic, clinical, or laboratory data., Conclusions: Our data show that almost 40% of patients with well-defined anti-Jo-1 ASSD with objective muscle impairment have a necrotising myopathy pattern in their muscle biopsies. Although this pattern is more classically related to immune-mediated necrotising myopathies, in association with clinical manifestations and the presence of anti-Jo-1 autoantibodies, this characteristic may lead to ASSD diagnosis.
- Published
- 2023
- Full Text
- View/download PDF
44. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
- Author
-
Aikawa NE, Kupa LVK, Silva CA, Saad CGS, Pasoto SG, Yuki EFN, Fusco SRG, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Pereira RMR, Chasin ACS, Shimabuco AY, Luppino-Assad AP, Leon EP, Lopes MH, Antonangelo L, Medeiros-Ribeiro AC, and Bonfa E
- Subjects
- Humans, COVID-19 Vaccines, BNT162 Vaccine, Prednisone, Rituximab, SARS-CoV-2, Antibodies, Viral, Immunoglobulin G, RNA, Messenger, Vaccines, Inactivated, COVID-19 prevention & control, Rheumatic Diseases drug therapy
- Abstract
Objectives: To assess immunogenicity of a heterologous fourth dose of an mRNA (BNT162b2) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in autoimmune rheumatic diseases (ARD) patients with poor/non-response to inactivated vaccine (Sinovac-CoronaVac)., Methods: A total of 164 ARD patients who were coronavirus disease 2019 (COVID-19) poor/non-responders (negative anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies-NAb) to the third dose of Sinovac-CoronaVac received an additional heterologous dose of mRNA (BNT162b2) 3 months after last dose. IgG and NAb were evaluated before and after the fourth dose., Results: Significant increases were observed after the fourth dose in IgG (66.4 vs 95.1%, P < 0.001), NAb positivity (5.5 vs 83.5%, P < 0.001) and geometric mean titre (29.5 vs 215.8 AU/ml, P < 0.001), and 28 (17.1%) remained poor/non-responders. Patients with negative IgG after a fourth dose were more frequently under rituximab (P = 0.001). Negative NAb was associated with older age (P = 0.015), RA (P = 0.002), SSc (P = 0.026), LEF (P = 0.016) and rituximab use (P = 0.007). In multiple logistic regression analysis, prednisone dose ≥7.5 mg/day (OR = 0.34; P = 0.047), LEF (OR = 0.32, P = 0.036) and rituximab use (OR = 0.19, P = 0.022) were independently associated with negative NAb after the fourth vaccine dose., Conclusions: This is the largest study to provide evidence of a remarkable humoral response after the fourth dose of heterologous mRNA SARS-CoV-2 vaccination in ARD patients with poor/non-response to the third dose of an inactivated vaccine. We further identified that treatment, particularly rituximab and prednisone, impaired antibody response to this additional dose., Trial Registration: ClinicalTrials.gov, https://clinicaltrials.gov, CoronavRheum #NCT04754698., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
45. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.
- Author
-
Pereira RMR, Dagostin MA, Caparbo VF, Sales LP, Pasoto SG, Silva CA, Yuki EFN, Saad CGS, Medeiros-Ribeiro AC, Kupa LVK, Fusco SRG, Martins VAO, Martins CCMF, Barbas CV, Shinjo SK, Aikawa NE, and Bonfa E
- Subjects
- Humans, Antibodies, Viral, Immunoglobulin G, Prednisone, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, COVID-19
- Abstract
Objective: To evaluate inactivated CoronaVac prime vaccination, antibody decay, booster dose, and safety in ANCA-Associated Vasculitis (AAV) patients., Methods: Fifty-three AAV patients and 106 Controls (CG) received CoronaVac on days: D0 (first dose), D28(second dose), and D210 (booster dose, 32 AAV: 32 CG). The primary outcome was immunogenicity after the second vaccine dose (day 69) assessed by Seroconversion Rates (SC) of anti-SARS-CoV-2 S1/S2 IgG and Neutralizing Antibodies (NAb). Secondary outcomes were safety, immunogenicity (D28/D240), 6-months antibody decay (D210) and the booster dose response (D240)., Results: At D69 SC (65.1% vs. 96.8%, p = 0.0001), GMT (21.3 UA/mL vs. 67.7 UA/mL, p < 0.001) and NAb- positivity (53.7% vs. 80.6%, p = 0.001) were moderate but lower in naïve-AAV patients than CG. Patients without SC used more often IS (93.3% vs. 53.3%, p = 0.015), mycophenolate mofetil (20% vs. 0%, p = 0.037) and prednisone (60.0% vs. 28.6%, p = 0.057) than seroconverted. NAb negativity in AAV patients was associated with prednisone treatment (57.9% vs. 18.2%, p = 0.015) and IS (84.2% vs. 55.0%, p = 0.046). Logistic regression analysis models showed that only prednisone was associated with lower seroconversion (OR = 0.2, 0,95% CI 0.05‒0.86, p = 0.030) and with lower NAb positivity (OR = 0.2, 0,95% CI 0.05‒0.88, p = 0.034). After six months (D69‒D210) a decrease in IgG positivity occurred in 32 AAV patients (15.7%, p = 0.074) and 32 CG (18.7%, p = 0.041). For the NAb positivity, the 6-month decrease was not significant (p = 0.114) whereas a major reduction occurred for CG (p < 0.001). A booster dose (D240) resulted in an increment in IgG-positivity (21.9%, p = 0.023) and NAb-positivity (34.4%, p = 0.006) in AAV patients. No moderate/severe adverse events attributable to the vaccine were observed., Conclusion: This study provides novel data on the excellent safety and moderate immunogenicity of CoronaVac in AAV patients. A six-month mild antibody waning was observed with a good response to the booster dose, although levels remained lower than CG (CoronavRheum-NCT04754698)., Competing Interests: Conflicts of interest The authors declare no conflicts of interest., (Copyright © 2022 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
46. Gathering patients and rheumatologists' perceptions to improve outcomes in idiopathic inflammatory myopathies.
- Author
-
Bertoglio IM, Abrahao GF, de Souza FHC, Miossi R, de Moraes PC, Shinjo SK, Bonfá E, and Lopes MRU
- Subjects
- Fatigue, Humans, Pain, Quality of Life, Myositis drug therapy, Rheumatologists
- Abstract
Objective: Therapeutic targets in Idiopathic Inflammatory Myopathies (IIM) are based on the opinions of physicians/specialists, which may not reflect the main concerns of patients. The authors, therefore, assessed the outcome concerns of patients with IIM and compared them with the concerns of rheumatologists in order to develop an IIM outcome standard set., Methods: Ninety-three IIM patients, 51 rheumatologists, and one physiotherapist were invited to participate. An open questionnaire was initially applied. The top 10 answers were selected and applied in a multiple-choice questionnaire, inquiring about the top 3 major concerns. Answers were compared, and the agreement rate was calculated. Concerns were gathered in an IIM outcome standard set with validated measures., Results: The top three outcome concerns raised by patients were medication side effects/muscle weakness/prevention functionality loss. The top three concerns among rheumatologists were to prevent loss of functionality/to ensure the quality of life/to achieve disease remission. Other's outcomes concerns only pointed out by patients were muscle pain/diffuse pain/skin lesions/fatigue. The agreement rate between both groups was 41%. Assessment of these parameters guided the development of an IIM standard set which included Myositis Disease Activity Assessment Visual Analogue Scale/Manual Muscle Testing/fatigue and pain Global Visual Analogue Scale/Health Assessment Questionnaire/level of physical activity., Conclusion: The authors propose a novel standard set to be pursued in IIM routine follow-up, which includes not only the main patients/rheumatologist outcome concerns but also additional important outcomes only indicated by patients. Future studies are necessary to confirm if this comprehensive approach will result in improved adherence and ultimately in better assistance., Competing Interests: Conflicts of interest The authors declare no conflicts of interest., (Copyright © 2022 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
47. Analysis of patient-physician discrepancy in global assessment of systemic autoimmune myopathy disease activity.
- Author
-
Cordeiro RA, Fischer FM, and Shinjo SK
- Subjects
- Adult, Cross-Sectional Studies, Humans, Physician-Patient Relations, Severity of Illness Index, Muscular Diseases, Physicians
- Abstract
Objectives: To compare the perception of disease activity (DA) between adult patients with systemic autoimmune myopathies (SAMs) and their physicians, and analyse possible sources of discordance., Methods: This cross-sectional study included 75 patients with SAMs. Patients and physicians rated the global DA on a 0-10 cm visual analogue scale. A discrepancy score was calculated by subtracting physician assessment from patient assessment. Three groups were defined: (I) no discrepancy: difference within -2.0 to +2.0; (II) negative discrepancy (ND): difference <-2.0 (patient underrated DA in relation to physcian); (III) positive discrepancy (PD): difference >+2.0 (patient overrated DA in relation to physician). Logistic regression was used to identify predictors of discordance., Results: Discordance in patient-physician assessment of DA was found in 21 (28%) cases. ND was observed in 3 (4%), PD in 18 (24%), and no discrepancy in 54 (72%) assessments. Due to the small number, ND cases were excluded from the analysis. PD was associated with older age, personal history of depression, past joint involvement, higher MMT-8 and lower extramuscular DA. In the regression model, for each additional year of age, the chance of PD increases, on average, by 9% (OR 1.09; 95%CI 1.01-1.17, p=0.034). Personal history of depression increases the chance of PD by 829% (OR 9.29; 95%CI 1.52-56.89, p=0.016)., Conclusions: Almost 30% of patients had discordance in DA assessment from their physicians. The majority of them overrated their DA. These patients tend to be older and are more likely to have personal history of depression, past joint involvement, and milder disease.
- Published
- 2022
- Full Text
- View/download PDF
48. Serum Myostatin and Follistatin Levels in Patients With Dermatomyositis and Polymyositis.
- Author
-
de Sordi CM, Dos Reis-Neto ET, Keppeke GD, Shinjo SK, and Sato EI
- Subjects
- Adult, Cross-Sectional Studies, Humans, Middle Aged, Dermatomyositis diagnosis, Follistatin blood, Myostatin blood, Polymyositis diagnosis
- Abstract
Background: Myostatin is a protein in the TGF-β family that negatively regulates muscle mass, and follistatin is a myostatin antagonist., Objective: The aim of this study was to measure serum levels of myostatin and follistatin in idiopathic inflammatory myopathy patients and correlate these levels with muscle strength, fatigue, functional capacity, damage, and serum levels of muscle enzymes., Methods: This was a multicenter cross-sectional study including 50 patients (34 dermatomyositis and 16 polymyositis [PM]) and 52 healthy individuals (control group [CG]). The disease status was evaluated according to the International Myositis Assessment & Clinical Studies. Fatigue was rated according to the Fatigue Severity Scale, and body composition was measured using dual-energy x-ray emission densitometry. Myostatin and follistatin were measured using enzyme-linked immunosorbent assays., Results: Mean age was 50.9 ± 14.0 years, and mean disease duration was 89.2 ± 80.9 months. There were no differences in levels of myostatin (14.15 ± 9.65 vs. 10.97 ± 6.77 ng/mL; p = 0.131) or follistatin (0.53 ± 0.71 vs. 0.49 ± 0.60 ng/mL; p = 0.968) between patients and the CG. However, myostatin levels were higher in PM than CG (16.9 ± 12.1 vs. 11.0 ± 6.8 ng/mL; p = 0.036). There was no difference in serum myostatin among patients with and without low lean mass. Patients not treated with corticosteroids had higher serum levels of myostatin than the CG. There was a weak negative correlation between follistatin and Manual Muscle Testing and a Subset of Eight Muscles and a weak positive correlation between follistatin and Healthy Assessment Questionnaire., Conclusions: Serum levels of myostatin and follistatin did not differ between dermatomyositis and PM patients and control subjects. The assessment of serum levels of myostatin and follistatin in idiopathic inflammatory myopathy patients seems not to be helpful in clinical practice., Competing Interests: The authors declare no conflict of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
49. Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: Bimodal Pattern of Onset and Treatment Response.
- Author
-
Fargetti S, Ugolini-Lopes MR, Pasoto SG, Seguro LPC, Shinjo SK, Bonfa E, and Borba EF
- Subjects
- Humans, Immunosuppressive Agents therapeutic use, Prednisone, Retrospective Studies, Severity of Illness Index, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic drug therapy, Peripheral Nervous System Diseases diagnosis, Peripheral Nervous System Diseases epidemiology, Peripheral Nervous System Diseases etiology
- Abstract
Background/objective: Our aim was to describe the short- and long-term outcome of peripheral neuropathy (PN) attributed exclusively to systemic lupus erythematosus (SLE)., Methods: Systemic lupus erythematosus patients with defined PN (clinical and electroneuromyography) were retrospectively evaluated at onset, 1-year, and 5-year follow-up using a standardized electronic chart database that started in 2000. Exclusion criteria were comorbidities, drugs, and infections. Age-, sex-, and disease duration-matched SLE patients without PN were selected as controls., Results: Lupus PN was identified in 38 (1.8%) of 2074 patients, and almost two thirds had PN onset in the first 5 years of SLE (63.2%). Peripheral neuropathy SLE had higher frequencies of cutaneous vasculitis (50% vs 21.1%, p = 0.002), lymphopenia (60.5% vs 36.8%, p = 0.027), anti-Sm (52.6% vs 27.6%, p = 0.013), and higher SLEDAI-2K scores (11.5 ± 10.5 vs 4.9 ± 6.7, p < 0.001) compared with controls. The most common type was polyneuropathy (71.1%) with sensory-motor pattern (68.4%). At PN diagnosis, all patients received glucocorticoid and 97.4% started immunosuppressive therapy (50% intravenous cyclophosphamide, 42.1% azathioprine). After 1-year follow-up, 92.1% had a favorable outcome with complete (36.8%) or partial remission (55.2%), in parallel with a decrease in prednisone dose (48.3 ± 17.9 vs 15.3 ± 13.4 mg/d, p < 0.001), symptomatic therapy (57.9% vs 29.7%, p = 0.02), and SLEDAI-2K score (11.5 ± 10.5 vs 1.7 ± 3.7, p < 0.001). SLEDAI-2K scores were higher in patients who had PN onset with less than 1 year of SLE duration, compared with those with more than 5 years of disease (21.3 ± 9.1 vs 3.9 ± 5.3, p < 0.001). Early-PN-onset group had a better response to treatment (complete remission at 1-year follow-up 61.5% vs 25%, p = 0.039). At 5-year follow-up, 89.3% remained with complete/partial remission., Conclusions: Peripheral neuropathy attributed to SLE itself is a rare manifestation with a bimodal pattern, characterized by a predominant early-onset group associated with high disease activity and a higher rate of complete remission, and a late-onset group with low disease activity and a partial therapy response., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
50. Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis.
- Author
-
Silva MG, Oba-Shinjo SM, Marie SKN, and Shinjo SK
- Subjects
- Adult, Case-Control Studies, Cross-Sectional Studies, Cytokines, Female, Humans, Severity of Illness Index, Dermatomyositis blood, Dermatomyositis immunology, Interleukin-17 blood, Polymyositis blood, Polymyositis immunology
- Abstract
Objectives: To assess serum interleukin (IL)-17A levels in patients with dermatomyositis (DM) and polymyositis (PM) and correlate them with the demographic, clinical, laboratory and therapeutic data of these diseases., Methods: This was a cross-sectional, single-centre study that included defined DM and PM patients who were age-, gender- and ethnicity-matched to healthy individuals. Serum IL-17A analysis, as well as analysis for other cytokines (IL-6, TNFα and IFNγ), was performed by multiplex immunoassay. The disease status parameters were based on the International Myositis Assessment and Clinical Studies Group (IMACS) set scores., Results: Eighty DM, 32 PM patients and 104 healthy individuals were enrolled. Mean age of patients with DM and PM was 46.0 and 47.7, respectively, with a predominance of women and white ethnicity in both groups. Overall, clinical, laboratory, therapeutic, and current disease status were similar among patients with DM and PM. Median serum IL-17A level was higher in patients with PM and DM than the control group (0.73 vs. 0.49 vs. 0.35 pg/mL, respectively; p<0.050) and higher in PM when compared to DM (p<0.001). In DM, serum IL-17A levels were associated with cumulative cutaneous lesions, IMACS parameters, and serum IL-6 and IFNγ levels. In PM, serum IL-17A levels correlated with patients' current age, IMACS parameters and serum TNFα and IFNγ levels., Conclusions: Serum IL-17A levels are not only increased, but also associated with disease activity in patients with DM and PM. Our data strongly suggest that IL-17A may be a biomarker of disease activity for these systemic autoimmune myopathies.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.